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Objectives: Dementia with Lewy bodies (DLB) is a major cause of degenerative
dementia, yet the diagnosis is often missed or mistaken for Alzheimer's disease
(AD). We assessed whether the revised Addenbrooke's Cognitive Examination
(ACE‐R), a brief test for dementia, differentiates DLB from AD.
Methods: We first compared baseline ACE‐R performance in 76 individuals with
DLB, 40 individuals with AD and 66 healthy controls. We then investigated the
diagnostic accuracy of a simple standardised ‘memory/visuospatial’ ratio calculated
from the ACE‐R subscores. Finally, as a comparison a logistic regression machine
learning algorithm was trained to classify between DLB and AD.
Results: Individuals with AD had poorer memory (p = 0.001) and individuals with
DLB had poorer visuospatial function (p = 0.005). Receiver operating characteristics
curves confirmed that the ACE‐R total score could differentiate dementia from non‐
dementia cases with 98% accuracy, but could not discriminate between dementia
types (50%, or chance‐level accuracy). However, a ‘memory/visuospatial’ ratio ≥1.1
differentiated DLB from AD with 82% sensitivity, 68% specificity and 77% mean
accuracy. The machine learning classifier did not improve the overall diagnostic
accuracy (74%) of the simple ACE‐R subscores ratio.
Conclusions: The ACE‐R‐based ‘memory/visuospatial’ ratio, but not total score,
demonstrates good clinical utility for the differential diagnosis of DLB from AD.
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INTRODUCTION
Dementia with Lewy bodies (DLB) is characterised by recurrent
visual hallucinations, parkinsonian motor symptoms, rapid eye
movement (REM) sleep behaviour disorder and fluctuating cognitive
impairment.1 Although DLB is one of the major causes of degenera-
tive dementia, early diagnosis remains challenging. Alzheimer's dis-
ease (AD) and movement disorders are among the most frequent
misdiagnoses, largely due to shared symptomology (e.g., spontaneous
extrapyramidal motor features2) and difficulty to detect cognitive
impairment early. Identifying the presence of DLB by clinical
assessment is further complicated by dementia due to co‐occurring
AD.3 Overlapping neuropsychiatric symptoms can also lead to
misdiagnosis.4 Individuals with DLB may benefit from the treatment
of Parkinsonism or other autonomic symptoms, but adversely react
to neuroleptics, with increased morbidity and mortality in severe
cases.5 DLB specific management pathways have recently been
developed,6 but an accurate diagnosis is clearly needed for
individuals to benefit from these.
Neuropathological examination has indicated that around 50%
of cases with DLB pathology presented with global impairments
typical of AD, leading to considerable under‐diagnosis.2 Individuals
with DLB are given more prior alternative diagnosis, undertake
more brain scans and experience longer delays before receiving a
final diagnosis than other dementia types.7 Cognitive assessment
provides a reliable and domain‐specific profile of impairment.
Memory decline associated with medial temporal atrophy is highly
characteristic of AD, whereas deficits in visuospatial function
compared to relatively intact memory and object naming are more
pronounced in DLB.1,8 Given the complex clinical heterogeneity of
DLB and considerable variation in regional diagnostic rates,9
comprehensive examination is required for making a probable
diagnosis (i.e., the presence of dementia with at least two core
features1). The potential utility of cognitive markers for minimising
the number of false‐negative and false‐positive cases is less clear.
In a cohort with established accuracy of a clinical diagnosis verified
against post‐mortem evaluation, a memory to praxis ratio derived
from subscales of the cognition section (CAMCOG10) of the
Cambridge Examination for Mental Disorders of the Elderly
showed 63% sensitivity and 84% specificity at the optimal cut‐off
score (≥0.4) for discriminating DLB from AD.11 However, the value
of other brief and widely used cognitive scales has not been
reported.
The revised Addenbrooke's Cognitive Examination12 (ACE‐R) is
a brief cognitive screening assessment that is sensitive to the early
stages of dementia and able to differentiate between dementia
subtypes.12,13 Modifications to the original version were made to
facilitate easier administration, remove insensitive items and include
parallel versions of the name and address recall. The Addenbrooke's
Cognitive Examination‐Revised (ACE‐R) also includes more tests of
visuospatial abilities relevant to cognitive impairment in DLB than
the CAMCOG and Mini‐Mental State Examination (MMSE).14
Increased sensitivity and specificity of the ACE‐R has been partly
attributed to expansion of the visuospatial domain.12 This is
particularly important, as others have suggested that clinical inter-
pretation of the ACE‐R should be guided by its latent‐variable
structure, in which visuospatial abilities have been identified as
a notable factor.15 Previous studies have used the ACE‐derived
‘Verbal + Language/Orientation + Memory (VLOM)’ ratio to
discriminate frontotemporal dementia (FTD) from AD, with mixed
success.13,16,17 Others have used the verbal fluency subscore for the
differential diagnosis of parkinsonian syndromes18 and the total
ACE‐R score to differentiate between AD and late‐life depression.19
Yet no studies to date have used this instrument to distinguish DLB
from other dementia types. To redress this, we calculated a simple
standardised ‘memory/visuospatial’ ratio similar to Ballard and
colleagues,11 but using the ACE‐R subscores most likely to
discriminate between DLB and AD.
Another approach for combining subscores would be to apply
machining (ML) techniques. As cognition is multivariate, the tradi-
tional reliance on univariate tests weakens the ability to detect group
differences. For example, subscores in combination may be much
more sensitive than when considered in isolation. ML has been
previously used to ‘train’ models that can detect and differentiate
between pathologies.20,21 An established ML algorithm used for
classification is logistic regression.22 Using linear rather than deep
learning models allows for features underpinning any group
discrimination to be readily understood. This affords a good balance
of inference power (accuracy) and transparency (interpretability). For
this reason we considered logistic regression as a good model
comparator. Performance of our ‘memory/visuospatial’ ratio could
thus be interpreted against commonly used predictive modelling.
Assuming equal performance of the two models, the advantage of our
ratio is that it is much easier to use than a ML classifier (e.g., quicker
to calculate; can be calculated with paper and pencil using raw
scores; no specialist training is required).
Key points
� Discriminating between dementia with Lewy bodies
(DLB) and Alzheimer's disease (AD) is challenging,
especially in early stages
� A ‘memory/visuospatial’ ratio calculated from the widely
used revised Addenbrooke's Cognitive Examination
(ACE‐R) accurately differentiated DLB from AD, whereas
the ACE‐R total score performed at chance level
� Routinely collected cognitive assessment provides a brief
and easily accessible method for assisting clinical
diagnosis
� Improving diagnostic accuracy has several advantages
for individuals with DLB and their carers, including bet-
ter provision of support services and disease specific
management
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We first aimed to replicate the clinical utility of the ACE‐R for
differentiating between dementia and non‐dementia in our sample.
Secondly, using receiver operating characteristics (ROCs) curves, we
tested the hypothesis that the ‘memory/visuospatial’ ratio would
discriminate DLB from AD. As a comparison, we used a ML classifier
with the ACE‐R subscales as features and compared its overall mean
accuracy with the overall mean accuracy of the ‘memory/visuospatial’
ratio. Establishing the accuracy of the ‘memory/visuospatial’ ratio for
the differential diagnosis of DLB from AD could lead to its use in
memory clinic and dementia assessment settings, whereby a simple
and easily calculated score could assist with clinical diagnosis,




Participant data were obtained from baseline visits of three UK
dementia studies: Neuroimaging of Inflammation in Memory and
Other Disorders23 (NIMROD, 13/EE/0104, Cambridge); the Multi-
modal Imaging of Lewy Body Disorders study (MILOS, 16/EE/0531,
Cambridge); and Amyloid Imaging for Phenotyping Lewy Body De-
mentia24 (AMPLE, 13/NE/0064, Newcastle). Volunteers with Lewy
body dementia met either the 2005 consensus criteria25 (NIMROD,
AMPLE) or the 2017 revised criteria26 (MILOS) for probable DLB.
Participants with AD met the diagnostic criteria for probable AD as
defined by the National Institute of Neurological and Communica-
tive Disorders and Stroke (NINCDS) and the AD and Related Dis-
orders Association (ADRDA).27 Control participants were healthy
adults with an absence of regular memory problems, signs or
symptoms suggestive of dementia (including MMSE28 score >26) or
significant medical illnesses. Participants were aged 50 years
and older. Exclusion criteria were any co‐existing neurological
conditions and a history of substance dependence. All participants
provided informed written consent.
Addenbrooke's Cognitive Examination‐Revised
The ACE‐R12 is an objective and reliable 100‐point test that evaluates
multiple cognitive domains: orientation/attention (18‐points), mem-
ory (26‐points), verbal fluency (14‐points), language (26‐points) and
visuospatial ability (16‐points). The memory subscale comprises items
of semantic and episodic content (e.g., recall, anterograde, recognition)
and the visuospatial subscale includes copying overlapping pentagons,
copying a wire cube and free drawing a clock. The ACE‐R has shown
good reliability (Cronbach's alpha = 0.08) with two‐cut off scores
previously identified for detecting people with dementia (88/100:
sensitivity = 0.94, specificity = 0.89 and 82/100: sensitivity = 0.84,
specificity = 1.0); the likelihood of having dementia at the latter score
was 100:112. The test takes approximately 20 min to complete.
Statistical analyses and predictive modelling
Basic demographic information was analysed using one‐way analysis
of variance, independent samples t‐tests and chi‐square tests
as appropriate. Due to non‐normal distributions and highly
skewed cognitive data, the ACE‐R subscales and total score were Z‐
transformed and analysed using Kruskal–Wallis H tests (for three‐
group comparisons) and Mann–Whitney U tests (clinical group
comparisons only). Data were analysed using SPSS version 25.
A logistic regression ML model29 was trained to classify between
DLB and AD, excluding the healthy control participants. The model
was written as follows:
log odds DLB ðscoresÞ ¼ wattention ∗ sattention þ wmemory ∗ smemory
þ wverbal fluency ∗ sverbal fluency þ wlanguage ∗ slanguage þ wvisuospatial
∗ svisuospatial
where, each s is an ACE‐R subscore (orientation/attention, memory,
verbal fluency, language and visuospatial ability) acting as a feature in
the model and each w is its associated weight. Disease probability
can then be computed by applying a sofmax function:
PðDLBÞ ¼
elog odds DLB
1þ elog odds DLB
; PðADÞ ¼ 1 − PðDLBÞ
where, ex is the natural exponential function. The final prediction is
then obtained by setting a threshold (i.e., when the probability of DLB
is higher than 0.5, the model predicts DLB, and vice versa for AD).
Each subscore is normalised by subtracting the mean and dividing by
the standard deviation, both obtained from the full dataset. In order
to report diagnostic accuracy that generalises well, we used a L2
regulariser with a coefficient C = 1 on each weight during training,
and trained the model using 85% of the data (randomly selected). We
then evaluated the accuracy, sensitivity and specificity of the classi-
fier using the remaining 15% of the data (test set). This process was
repeated with 20 different random seeds. All procedures were coded




Demographic information for the DLB (n = 76), AD (n = 40) and
healthy control (n = 66) groups are presented in Table 1. Participants
were predominantly male (73.6%) with a mean age of 73.8 years
(SD= 7.10). The three‐groups were well matched for age, but sex ratio
and years in education were significantly different. However, sex ratio
and years in education did not significantly differ between the DLB
and AD groups. Participants in these groups were in mild‐to‐moderate
disease stages, as reflected by total ACE‐R and MMSE scores.
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Differentiating dementia and non‐dementia
participants
One hundred sixteen individuals with dementia and 66 control
participants were included in the model. An ACE‐R cut‐off score of
88/100 showed optimal sensitivity (96%) and specificity (88%) for
identifying dementia from non‐dementia. Similarly, a cut‐off score of
82/100 revealed high sensitivity (83%) and greater specificity (97%.)
The ROC curve plotting the trade‐off between the true positive rate
(sensitivity) and false positive rate (1—specificity) showed strong
clinical utility of the ACE‐R total score for detecting dementia (area
under the curve, AUC = 0.98) (Figure 1).
Differentiating DLB from AD with the ‘memory/
visuospatial’ ratio
As expected, the MMSE total score, ACE‐R subscales and ACE‐R
total score were highly significantly different between the three
groups (all p's < 0.001; Table 1; raw scores are presented). Follow‐up
comparisons between the clinical groups revealed that, as would be
expected, individuals with AD had significantly poorer memory
(p = 0.001), whereas individuals with DLB had significantly poorer
visuospatial ability (p = 0.005). To determine the diagnostic accuracy
of these subscales, in keeping with our hypothesis, we calculated a
‘memory/visuospatial’ ratio and plotted its ROC curve along with the
ROC curve for the ACE‐R total score for comparison (Figure 2). The
ROC curves showed that the ‘memory/visuospatial’ ratio was a good
marker for detecting DLB (AUC = 0.79). In contrast, the ACE‐R total
score showed no diagnostic ability for predicting dementia subtypes
(AUC = 0.50). In our sample, a memory/visuospatial score ≥1.1 highly
differentiated DLB from AD, with a sensitivity of 82%, a specificity of
68%, a positive predictive value of 82% and a negative predictive
value of 65%. The cut‐off of 1.1 showed an overall mean accuracy of
77% to correctly differentiate DLB from AD.
Differentiating DLB from AD with machine learning
We then used a logistic regression model to determine the weight of
each ACE‐R subscale after training. It was shown that the memory
and visuospatial subscales were the two domains that highly influ-
enced the model, being the furthest away from zero (Figure 3).
Smaller values assigned to the attention/orientation, verbal fluency
and language domains indicated low influence of these features on
the model. Similar to our ‘memory/visuospatial’ ratio, the logistic
regression model showed 78% sensitivity, 63% specificity and 74%
overall mean accuracy for differentiating between DLB and AD.
DISCUSSION
The tendency to under‐diagnose DLB prevents appropriate treat-
ment and disease management, which in turn increases burden on
individuals with DLB and their caregivers. Higher diagnostic rates
reported in secondary care than in the community likely reflects
better accuracy within a specialist setting.9 A brief cognitive
assessment such as the ACE‐R may thus provide a more easily
accessible method for assisting diagnosis. We first confirmed that the
ACE‐R‐total thresholds of 82 and 88 (out of 100) differentiated
between dementia and non‐dementia participants with extremely
high accuracy (98%). Our optimal cut‐offs were similar to those
previously reported in other samples,12,13,16 replicating the validity of
the ACE‐R for accurately detecting dementia. Group differences on
TAB L E 1 Demographic characteristics and ACE‐R performance (means and standard deviations) by group
DLB n = 76 AD n = 40 HC n = 66 3‐group comparisons DLB versus AD
Demographics
Age (years) 74.8 (6.3) 73.8 (8.6) 72.6 (6.9) F (2,179) = 1.88, p = 0.16 t (61.90) = 0.69, p = 0.50
Education (years) 11.8 (3.1) 12.5 (2.9) 14.1 (3.4) F (2,179) = 9.80, p < 0.001 t (114) = −1.15, p = 0.25
Sex (male: female) 64: 12 28: 12 42: 24 X2 = 8.05, p = 0.02 X2 = 2.97, p = 0.09
MMSE 22.7 (4.4) 22.3 (1.13) 28.9 (1.1) X2 (2) = 104.53 p < 0.001 U = 1467.00, p = 0.76
ACE‐R
Attention/orientation 14.1 (3.3) 14.3 (3.6) 17.9 (0.4) X2 (2) = 83.77, p < 0.001 U = 1431.00, p = 0.60
Memory 14.9 (5.2) 11.5 (5.3) 23.6 (2.5) X2 (2) = 106.60, p < 0.001 U = 973.50, p = 0.001
Fluency 6.2 (3.1) 6.6 (3.2) 11.7 (2.1) X2 (2) = 89.36, p < 0.001 U = 1390.50, p = 0.45
Language 22.3 (2.9) 22.1 (3.8) 25.1 (1.0) X2 (2) = 51.17, p < 0.001 U = 1469.50, p = 0.77
Visuospatial 10.2 (3.9) 12.3 (3.4) 15.6 (0.8) X2 (2) = 91.13, p < 0.001 U = 1041.50, p = 0.005
Total 67.9 (14.2) 66.7 (15.5) 93.9 (4.7) X2 (2) = 115.25, p < 0.001 U = 1519.50, p = 0.10
Note: Entries in bold indicates significant findings.
Abbreviations: ACE‐R, revised Addenbrooke’s Cognitive Examination; AD, Alzheimer’s disease; DLB, Dementia with Lewy bodies; HC, Healthy controls;
MMSE, Mini‐Mental State Examination.
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the ACE‐R subscales revealed the expected pattern of cognitive
impairment between our dementia groups, such that individuals with
AD showed poorer memory and individuals with DLB showed poorer
visuospatial ability. The remaining subscales did not significantly
differ between the two groups. Poor memory performance in
individuals with AD is largely associated with structural degeneration
of the medial temporal lobe.1,8 Early and severe deficits in visuo-
spatial abilities have been shown to predict visual hallucinations in
individuals with DLB, typically thought to reflect accumulation of
alpha‐synuclein rather than AD‐related pathology.30 Following the
memory to praxis ratio previously used to discriminate DLB from AD
and vascular dementia in a consecutive cohort study,11 we calculated
an ACE‐R derived ‘memory/visuospatial’ ratio to determine the
diagnostic prediction of the observed cognitive differences. We
found that the optimal cut‐off score showed good sensitivity and
specificity for differentiating DLB from AD. However, the relatively
low negative predictive value (i.e., number of false‐negatives) of our
‘memory/visuospatial’ ratio indicated that some individuals with AD
F I GUR E 1 The ROC curve plotting the
trade‐off between the true positive rate
(sensitivity) and false positive rate (1—
specificity) showed strong clinical utility of the
ACE‐R total score for detecting dementia
(AUC = 0.98); Abbreviations: ACE‐R, revised
Addenbrooke's Cognitive Examination; AUC,
area under the curve; ROC, receiver operating
characteristics
F I GUR E 2 The ‘memory/visuospatial ratio
showed good accuracy for detecting DLB
(AUC = 0.79); the ACE‐R total score performed
at chance level (AUC = 0.50). A cut‐off score of
1.1 differentiated DLB from AD with 82%
sensitivity, 68% specificity, 82% positive
predictive value and 65% negative predictive
value; Abbreviations: ACE‐R, revised
Addenbrooke's Cognitive Examination; AD,
Alzheimer's disease; AUC, area under the curve;
DLB, Dementia with Lewy bodies
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were incorrectly classified as DLB in our sample. This may be due to a
subset of individuals with AD presenting with multi‐domain cognitive
dysfunction, in which lower scores assigned to impaired visuospatial
ability biased classification toward DLB. As such, our ratio should be
used as an extra tool alongside supporting and core clinical features
(e.g., REM sleep behaviour disorder) as well as proposed biomarkers
(e.g., dopaminergic abnormalities in the basal ganglia) of DLB when
making a diagnosis. Importantly, the ROC curves further indicated
that the total ACE‐R score had no discrimination capacity, perform-
ing only at chance level.
The ML classifier did not improve the overall diagnostic accu-
racy (74%) of the simple ACE‐R subscores ratio. This is likely due to
the use of linear models, which generalise well and are the easiest
to interpret. Although non‐linear models may give higher training
performance, they are more sensitive to overfitting and suffer from
lower predictive accuracy when evaluating subscores of new cases.
Sensitivity and specificity of the ML classifier showed similar values
to the ‘memory/visuospatial’ ratio, suggesting comparable
performance between the two methods. When interpreting the
weights of the ML classifier, the small values assigned to the
attention/orientation, language and verbal fluency subscales support
the lack of significant differences found on these subscores between
our dementia groups (see Figure 3). Higher weights given to the
memory and visuospatial subscores were again consistent with the
expected profile of cognitive impairment and further reflect the
latent‐variable structure of the ACE‐R, in which combined memory
measures (anterograde retrieval and working memory items) and
visuospatial ability are among the constructs best measured by the
test. Including core diagnostic symptoms in our classifier, such as
the presence or recent history of complex visual hallucinations,
would likely have improved its discrimination threshold. However,
unlike impairments in visuospatial abilities, visual hallucinations
often do not manifest at initial presentation,31 and our aim was to
assess a cognitive marker that could be calculated at any time point
in the disease.
Our findings complement previous studies using the ACE‐R
subscales to detect specific dementia (e.g., the ‘VLOM’ ratio for
FTD13; the verbal fluency subscore for idiopathic PD18). It is worth
noting that forms of standardised cognitive assessment have been
used to differentiate between dementia types. For example, visual
perceptual items of the Wechsler Adult Intelligence Scale‐revised
and the Wechsler Memory Scale‐revised have shown to differentiate
DLB from AD32; a ML classifier has identified poor paired associates
learning as a highly accurate predictor of converting to AD20; and
disease‐specific profiles of cognitive impairment have shown to
relate to discrete signatures of gait in DLB and AD.33 Together,
these studies indicate that objective and reliable tests of cognitive
function are useful tools for illness detection and differentiation.
They also provide less costly evaluation than brain imaging, and in
the case of the ACE‐R, does not require specialist test equipment to
administer.
There are limitations to our study. We did not separate amyloid‐
positive from amyloid‐negative status, although amyloid deposition
was shown not to relate to cognitive or functional impairment in a
subset of our DLB sample.24 Inclusion of longitudinal ACE‐R data
would have been useful for monitoring the rate of cognitive change (i.
e., clinically significant decline) as an index of disease progression.
Similarly, post‐mortem data would have allowed us to pathologically
validate results from the ‘memory/visuospatial’ differentiation. As
cases in our sample were mild‐to‐moderate, future work could
investigate the utility of our ratio in the prodromal stages (mild
cognitive impairment) of both diseases. Determining the diagnostic
accuracy of the ‘memory/visuospatial’ ratio with data from the
Addenbrooke's cognitive examination III (ACE‐III), which substituted
items from the MMSE, would also be an important next step. We
expect similar results given the same proportion of subscores and
total score between the two instruments, with only one item of in-
terest differing in the visuospatial domain (copying the intersecting
pentagon was replaced with an infinity diagram). Although not yet
used for the differential diagnosis of DLB, sensitivity and specificity
F I GUR E 3 Weighted cognitive features
(means and standard deviations for each ACE‐R
subscore) of the logistic regression model;
Abbreviation: ACE‐R, revised Addenbrooke's
Cognitive Examination
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of the ACE‐III for identifying other dementias (AD and FTD) have
shown favourable comparability with the ACE‐R.34
Our study has clinical implications. The ‘memory/visuospatial’ ra-
tio was calculated from routinely collected ACE‐R data, therefore
providing a simple cut‐off score that could be used by clinicians to
assist diagnosis. Improving the diagnostic accuracy of DLB has several
advantages. First, treatment strategy could be optimised, such that
cholinesterase inhibitors may be introduced, whereas anticholinergics
and neuroleptic medications should be carefully monitored or avoi-
ded.1,5 Second, receiving an accurate diagnosis earlier is important. As
individuals with DLB spend almost four additional days in hospital per
year than individuals with AD,35 earlier diagnosis could minimise the
number of acute admissions, thereby reducing inpatient costs and
improving patient wellbeing. It may also help alleviate anxiety precip-
itated by the onset of neuropsychiatric, movement disorder or auto-
nomic symptoms not seen in AD. Finally, increasing the true positive
diagnostic rate would ensure selection of appropriate volunteers for
participation in clinical trials of potential anti‐dementia therapies.
Overall, this study confirmed the reliability of the ACE‐R for
detecting dementia in a pooled clinical sample, which further showed
good discrimination between DLB and AD. These findings demon-
strate that the proportion of impaired memory to visuospatial ability
could be extended from the CAMCOG to the ACE‐R in the assess-
ment of DLB. Markers of cognitive decline are key indicators of
disease severity and progression that could also be used to calculate
a simple cut‐off score to assist diagnosis. Future studies could
combine cognitive performance with converging clinical and fluid
biomarkers of DLB as well as structural and positron emission to-
mography (PET) imaging to test a predictive model built using
multimodal features (e.g., by including visual hallucinations31; over-
lapping neuropsychiatric symptoms36; striatal dopamine transporter
imaging2). Early and accurate clinical diagnosis of DLB helps optimise
decision‐making and disease specific management in order to achieve
the best possible outcome for those affected.
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